A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
This research study is for children and young adults, aged 2 to 21, who have neuroblastoma that has either returned after treatment or hasn't responded to previous therapies. The main goal is to test a new medicine named LY3295668 erbumine. We want to learn if this medicine is safe for patients and how their bodies react to it. Participants will take the medicine, and doctors will carefully monitor them for any side effects. This study aims to gather important information that could help develop new ways to treat neuroblastoma in the future. It's an early-stage study, meaning it's one of the first times this medicine is being tested in people.
במבט חטוף
על מה המחקר הזה?
This study is focused on a type of cancer called neuroblastoma, which often affects young children. Sometimes, after initial treatments, neuroblastoma might come back (what doctors call 'relapsed') or it might not respond as well as hoped to existing treatments (known as 'refractory'). When this happens, we need to find new and effective ways to help.
That's where this study comes in. Researchers are investigating a new medicine called LY3295668 erbumine. The main purpose of this early study (called 'Phase 1') is to see if this new medicine is safe for young people with relapsed or refractory neuroblastoma. Doctors will give the medicine and watch carefully to see how patients respond and if there are any side effects. They'll also check to see what dose is safe.
The information gathered from studies like this is really important. It helps scientists understand how new medicines work and if they could potentially be helpful for patients in the future. It's a key step in developing better treatments and improving the lives of children and young adults facing neuroblastoma.
נקודות עיקריות
- This study is testing a new medicine for neuroblastoma that has come back or not responded to other treatments.
- It's for children and young people aged 2 to 21.
- The main goal is to see if the new medicine is safe.
- Participants will take the medicine as capsules and have regular check-ups.
- It's an early-stage study, meaning we are learning about this medicine for the first time in people.
- אתה יכול להפסיק להשתתף בכל עת.
מי עשוי להיות זכאי?
To join this study, children and young people need to be between 2 and 21 years old and have neuroblastoma that has come back or hasn't responded to earlier treatments. The disease must be active in areas like their bones, bone marrow, or soft tissues. Participants also need to be able to swallow capsules, as the study medicine is taken this way.
There are also some reasons why someone might not be able to join. For example, if they've had certain types of transplants (like a stem cell or organ transplant), or if the neuroblastoma has spread to their brain or spinal cord without being treated. They also shouldn't have other serious illnesses, problems absorbing medicines, or a known allergy to any part of the study treatment. If they've taken similar medicines recently or have certain active infections like HIV or hepatitis, this would also mean they can't take part.
האם מחקר זה יכול להתאים לך?
ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.
- Am I, or the person I care for, between 2 and 21 years old?
- Do I have neuroblastoma that has come back or not responded to previous treatments?
- Is the neuroblastoma currently active in my bone, bone marrow, or soft tissue?
- Am I able to swallow capsules?
- Have I had an organ or stem cell transplant?
- Do I have any other serious untreated diseases or active infections like HIV or hepatitis?
מה כרוך בהשתתפות?
If you decide to take part in this study, you will be given the study medicine, LY3295668 erbumine, which you will take as capsules. You will need to attend regular appointments at the hospital. At these visits, doctors will perform examinations and tests, which might include blood tests and scans, to check on your health and how you are responding to the medicine. They will also carefully watch for any side effects you might experience. The exact number and frequency of visits will be explained by the study team. They will also tell you the total length of time you will be involved in the study.
סיכונים ותועלות פוטנציאליים
מיקומים (17)
- מרכז רפואי UCSF במישן ביימיקוד מאומתסן פרנסיסקו, ארצות הברית
- בית החולים לילדים קולורדומיקוד מאומתאורורה, ארצות הברית
- University of Chicago - Comer Children's Hospitalמיקוד מאומתשיקגו, ארצות הברית
- מכון דנה-פרבר לסרטןמיקוד מאומתבוסטון, ארצות הברית
- Cincinnati Childrens Hospital Medical Centerמיקוד מאומתסינסינטי, ארצות הברית
- בית החולים לילדים של פילדלפיהמיקוד מאומתפילדלפיה, ארצות הברית
- Texas Childrens Hospitalמיקוד מאומתיוסטון, ארצות הברית
- Perth Children's Hospitalמיקוד מאומתפרת', אוסטרליה
- UZ Gentמיקוד מאומתגנט, בלגיה
- Centre Leon Berardמיקוד מאומתליון, צרפת
- Institut Curieמיקוד מאומתפריז, צרפת
- Universitätsklinikum Kölnמיקוד מאומתקלן, גרמניה
שאלות נפוצות
What is neuroblastoma?
Neuroblastoma is a type of cancer that often affects young children, starting in nerve tissue outside of the brain.
מה המשמעות של 'חזרה/עמידות'?
This means the neuroblastoma has either come back after previous treatment, or it hasn't responded well to earlier treatments.
מהו התרופה החדשה שנבדקת?
The new medicine is called LY3295668 erbumine. It's an early-stage medicine not yet widely available.
Will I get other cancer treatments during the study?
The study will focus on LY3295668 erbumine. Your doctor will discuss all your treatment options with you.
מי מממן את המחקר הזה?
Clinical trials are typically funded by pharmaceutical companies, government agencies, or charitable organisations. Your doctor can provide specific funding details for this study.
כיצד לגלות עוד
תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.
דיון
דיון קהילתי
מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.